Royalty Pharma (NASDAQ:RPRX) Reaches New 12-Month High – Should You Buy?

Royalty Pharma PLC (NASDAQ:RPRX) shares reached a new 52-week high during trading on Tuesday . The company traded as high as $50.50 and last traded at $50.3080, with a volume of 595 shares trading hands. The stock had previously closed at $50.20.

Royalty Pharma News Roundup

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Citigroup raised its price target on RPRX to $66 and reiterated a “buy” rating—implies ~31.5% upside from the current price. Read More.
• Positive Sentiment: JPMorgan boosted its price target to $58 and moved RPRX to “overweight”—implies ~15.5% upside from the current price. Read More.
• Positive Sentiment: Royalty Pharma reported Q1 results showing an EPS beat and portfolio/royalty receipts growth, and raised full‑year 2026 guidance for Portfolio Receipts (now expected $3,325M–$3,450M), supporting longer‑term cash‑generation thesis. Read More.
• Neutral Sentiment: Royalty Pharma will present at multiple investor conferences in May, increasing management visibility to investors and analysts. Read More.
• Neutral Sentiment: Coverage and transcripts of the Q1 earnings call indicate management is upbeat about growth prospects; useful for qualitative read on pipeline and cash receipts but not an immediate earnings surprise. Read More.
• Negative Sentiment: Despite the EPS beat, reported Q1 revenue (~$631M) came in well below analyst expectations (~$882M), a gap that likely pressured the stock as investors assess sustainability of top‑line receipts. Read More.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. boosted their target price on Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research note on Thursday. UBS Group lifted their price objective on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. Wall Street Zen cut Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. TD Cowen restated a “buy” rating on shares of Royalty Pharma in a report on Friday, February 27th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Royalty Pharma in a research note on Thursday, February 12th. Seven equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $53.71.

Royalty Pharma Trading Down 1.0%

The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.88. The company has a market capitalization of $28.96 billion, a P/E ratio of 37.19, a price-to-earnings-growth ratio of 3.22 and a beta of 0.40. The business has a fifty day moving average price of $47.52 and a 200 day moving average price of $42.66.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.13. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%.The business had revenue of $621.99 million for the quarter, compared to analyst estimates of $839.97 million. On average, analysts expect that Royalty Pharma PLC will post 5.08 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $0.235 dividend. The ex-dividend date is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.9%. Royalty Pharma’s dividend payout ratio (DPR) is 69.63%.

Insider Activity at Royalty Pharma

In other Royalty Pharma news, CFO Terrance P. Coyne sold 34,791 shares of Royalty Pharma stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total value of $1,731,895.98. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 139,164 shares of company stock valued at $6,624,902 over the last 90 days. Insiders own 18.84% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RPRX. Morgan Stanley grew its holdings in Royalty Pharma by 25.2% during the fourth quarter. Morgan Stanley now owns 55,274,069 shares of the biopharmaceutical company’s stock worth $2,135,790,000 after purchasing an additional 11,110,115 shares during the period. Capital International Investors raised its stake in Royalty Pharma by 14.3% in the fourth quarter. Capital International Investors now owns 31,104,309 shares of the biopharmaceutical company’s stock valued at $1,201,870,000 after buying an additional 3,891,615 shares during the period. State Street Corp raised its stake in Royalty Pharma by 3.7% in the fourth quarter. State Street Corp now owns 10,649,641 shares of the biopharmaceutical company’s stock valued at $411,502,000 after buying an additional 376,888 shares during the period. Geode Capital Management LLC lifted its position in shares of Royalty Pharma by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 7,719,843 shares of the biopharmaceutical company’s stock valued at $297,465,000 after buying an additional 102,430 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of Royalty Pharma by 9.7% in the fourth quarter. Victory Capital Management Inc. now owns 5,106,905 shares of the biopharmaceutical company’s stock valued at $197,331,000 after buying an additional 449,498 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.